Clinical trial
A Phase 1b/2, Open-Label, Multicenter, Single-Arm Study of Ivonescimab in Combination With Pemetrexed and Platinum-Based Chemotherapy as First-Line Treatment in Patients With Advanced Malignant Pleural Mesothelioma
NCT07885319 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2, Open-Label, Multicenter, Single-Arm Study of Ivonescimab in Combination With Pemetrexed and Platinum-Based Chemotherapy as First-Line Treatment in Patients With Advanced Malignant Pleural Mesothelioma
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- November 1, 2026
- Completion date
- November 30, 2028
- Enrollment
- 78 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
malignant pleural mesothelioma, advanced
Lead sponsor's other trials
Ruijin Hospital, most recent start first.
+673 more trials See the organization page
Similar trials
Same condition (Mesothelioma, Malignant) and phase, most recent start first.
+37 more trials See the condition page